Latest IBOT Stories
The last of the nationâ€™s first stair-climbing wheelchair was quietly sold this spring, with its high-price tag having resulted in disappointing sales.
WASHINGTON, May 13 /PRNewswire-USNewswire/ -- Dean Kamen, an inventor and entrepreneur, and Bill Chatfield, director of the Selective Service System, will discuss how a low Medicare reimbursement rate has put out of production a mobile wheelchair that could benefit wounded veterans, at a National Press Club Newsmakers press conference at 3 p.m.
Industrial Biotechnology Corp. (Pink Sheets: IBOT) has received a reiterated Speculative Buy rating with a price target of $2.20, by Beacon Analyst Victor Sula, Ph.D. The full report is available at http://www.beaconequity.com/adpages/IBOT.
Industrial Biotechnology Corp. (Pink Sheets: IBOT) has been rated Speculative Buy with a price target of $2.20 by Beacon Analyst, Victor Sula, Ph.D. The full report is available at http://www.beaconequity.com/adpages/IBOT.
- To say in too many words; to express verbosely.
- To express in too many words: sometimes used reflexively.
- The leading idea or a repeated phrase, as of a song or ballad; the refrain; burden.